As rBmTI-A reduced the concentrations of IL-5, IL-10, IL-13, and IL-17A, CrataBL reduced the numbers of IFN-γ, IL-4, IL-5, IL-13, and IL-17 positive cells in the airways and alveolar walls; both studies used an asthma model [21,22]. This evidence concerns the gene IL13 and asthma.